Kevin Koehler, MD
Hematology & Oncology · Greenville, SCNPI 1093034746
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,966 of the $9,628 with a category attached, or 82.7%. Amgen accounts for 61.0% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2021 at $5,852 and has fallen 98.7% since, to $78 in 2025.
Across 105 payments — averaging $91.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$6K
- Bristol Myers Squibb$2K
- Merck$231
- Novartis$204
- E.r. Squibb & Sons, L.L.C.$182
- Gilead$146
- plus $852 from 21 others
Across 10 payments — averaging $3221.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$21K
- Genentech, Inc.$11K
What the payments were for
- Consulting fees$7,96683%
- Food & beverage$1,57316%
- Education$891%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 5 | $5,875 |
| Bristol Myers Squibb | 4 | $2,137 |
| Merck | 16 | $231 |
| Novartis | 14 | $204 |
| E.r. Squibb & Sons, L.L.C. | 14 | $182 |
| Gilead(2 entities) | 2 | $146 |
| Pfizer | 11 | $123 |
| Lilly USA, LLC | 8 | $110 |
| AstraZeneca | 2 | $92 |
| Incyte Corporation | 1 | $78 |
| Sanofi | 5 | $73 |
| AbbVie | 3 | $69 |
| Regeneron Healthcare Solutions, Inc. | 2 | $58 |
| EMD Serono, Inc. | 3 | $41 |
| Genentech USA, Inc. | 2 | $27 |
| Heron Therapeutics, Inc. | 1 | $25 |
| EUSA Pharma (US) LLC | 1 | $23 |
| Tersera Therapeutics LLC | 2 | $22 |
| GSK | 1 | $19 |
| Johnson & Johnson | 1 | $16 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
| Rigel Pharmaceuticals, Inc. | 1 | $11 |
| Exelixis Inc. | 1 | $11 |
| Veracyte, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,628 in reported general payments places this provider in the 70th percentile of 166 hematology & oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 36 | $438,760 |
| EliquisApixaban | 67 | $66,364 |
| XareltoRivaroxaban | 17 | $14,998 |
| Abiraterone Acetate | 11 | $3,435 |
| Anastrozole | 115 | $2,590 |
| Hydroxyurea | 65 | $685 |
| Letrozole | 21 | $509 |
| Tamoxifen Citrate | 13 | $479 |
| Acyclovir | 28 | $305 |
| Prochlorperazine Maleate | 14 | $119 |
| Gabapentin | 15 | $88 |
| Prednisone | 22 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $123 | $66,36467 claims |
| Johnson & JohnsonXarelto | $16 | $14,99817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 166 hematology & oncology providers in South Carolina.
Other hematology & oncology in Greenville
- Suzanne FanningGreenville$927K
- Stephen DyarGreenville$413K
- Bhumika PatelGreenville$225K
- Joe StephensonGreenville$57K
- Elizabeth CullGreenville$16K
- Paige GanemGreenville$9K
- Vikas DemblaSpartanburg$568K
- Kashyap PatelRock Hill$379K
- Tondre BuckSpartanburg$366K
- Ming LimCharleston$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.